Compare Halliburton Company (HAL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Novartis AG — how do they compare? Halliburton Company trades at $32.44 (market cap $26.45B), while Novartis AG trades at $142.74 (market cap $274.00B). The key difference: Novartis AG is far larger — about 10.4× Halliburton Company's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Novartis AG for 82 Days on average.
| HAL | NVS | |
|---|---|---|
Market Cap | $26.45B | $274.00B |
Volume | 11,229,274 | 1,852,137 |
Sector | Energy | Health |
52-Week High | $42.98 | $168.62 |
52-Week Low | $21.82 | $121.80 |
Typical Hold Time | 89 Days | 82 Days |
Enterprise Value | $32.60B | $315.32B |
Dividend Yield | 2.14% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, with technical indicators showing bearish momentum. The stock has demonstrated consistent earnings beats in recent quarters and maintains solid profitability metrics including 7.16% net margin and 14.89% ROE. Recent developments include expansion into Venezuela through partnerships with Eneva and WESCA, along with a major contract win for Cyprus' Cronos gas project, positioning the company for international growth opportunities.
Despite near-term technical weakness, Halliburton presents value with a 16.62 P/E ratio and strong analyst support (73% buy ratings) targeting $43.11 consensus. Risks include oil price volatility and execution challenges in new international markets, but the company's diversified service portfolio and improving cash flow trends support long-term growth prospects in the energy services sector.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
